A Phase 3 interventional study of Clopidogrel and acetylsalicyclic acid (ASA) in Acute Coronary Disease and Angina Unstable, sponsored by Sanofi. Completed at 38 sites in 38 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-11-18.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Angina, Unstable with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Angina, Unstable · United States.
Among the 58 studies in Angina, Unstable with a site in United States, this one is the 2nd largest by enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2006, is one of 11 in phase 3, and was the 15th registered.
330 studies on the registry are indexed under Angina, Unstable; 44 are open to participants now.
Browse Angina, Unstable studies →2 of the 58 studies in Angina, Unstable with a site in United States are open now. Recruiting first, the newest first:
University of South Florida · Sites in United States
Ages 18+
University of Sao Paulo General Hospital · Sites in United States, Brazil
Ages 30+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Angina, Unstable studies recruiting now, 29 (85%) set no upper age limit and 3 (9%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 12 · Phase 3 13 · Phase 4 5
First in 1999; this study’s year is marked. 6 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25,086 is above the median of 217 across 200 interventional studies indexed under Angina, Unstable.
Median enrollment 305 across the 39 interventional studies, 500 across the 19 observational. Of the 47 that completed or were terminated, 18 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 58 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 3 studies filed under Angina, Unstable — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 58 studies in Angina, Unstable with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a percutaneous coronary intervention (PCI).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Clopidogrel · Drug: acetylsalicyclic acid (ASA)
Drug: Clopidogrel · Drug: acetylsalicyclic acid (ASA)
Drug: Clopidogrel · Drug: acetylsalicyclic acid (ASA)
Drug: Clopidogrel · Drug: acetylsalicyclic acid (ASA)
oral administration
Also known as: SR25990, Plavix
oral administration
First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison
The primary endpoint is the first occurrence of any of the following events: * Cardiovascular death (any death with a clear cardiovascular or unknown cause), * Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal) * Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal) reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC).
Time frame: 30 days
First Occurrence of CV Death / MI / Stroke - ASA Dose Comparison
Time frame: 30 days
First Occurrence of CV Death / MI / Stroke - Interaction Clopidogrel Treatment Regimen and ASA Dose Level
Time frame: 30 days
First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison in PCI Subgroup
Time frame: 30 days
Occurrence of Major Bleeding - Clopidogrel Dose Regimen Comparison
Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC.
Time frame: 30 days
Occurrence of Major Bleeding - ASA Dose Level Comparison
Time frame: 30 days
25086 patients were enrolled and randomized between June 2006 and August 2009 in 597 sites in 39 countries. Because the observed overall blinded event rate was substantially lower than expected, the number of patients to be enrolled was increased from 18000 to 20000, then to 25000.
| Milestone | Clopidogrel 300/75/75 mg + ASA Low Dose | Clopidogrel 300/75/75 mg + ASA High Dose | Clopidogrel 600/150/75 mg + ASA Low Dose | Clopidogrel 600/150/75 mg + ASA High Dose |
|---|---|---|---|---|
| Started | 6312 | 6254 | 6267 | 6253 |
| Treated with clopidogrel | 6271 | 6218 | 6228 | 6217 |
| Treated with asa | 6302 | 6251 | 6261 | 6247 |
| Completed | 6154 | 6107 | 6108 | 6122 |
| Not completed | 158 | 147 | 159 | 131 |
| Withdrew: Death | 156 | 144 | 158 | 129 |
| Withdrew: Lost to follow-up | 2 | 3 | 1 | 2 |
The primary endpoint is the first occurrence of any of the following events: * Cardiovascular death (any death with a clear cardiovascular or unknown cause), * Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal) * Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal) reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC).
| participants | Clopidogrel 300/75/75 mg + ASA | Clopidogrel 600/150/75 mg + ASA |
|---|---|---|
| CV death/MI/Stroke | 557 | 522 |
| - CV death | 222 | 226 |
| - MI (fatal or not) | 274 | 237 |
| - Stroke (fatal or not) | 61 | 59 |
Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC.
| participants | Clopidogrel 300/75/75 mg + ASA | Clopidogrel 600/150/75 mg + ASA |
|---|---|---|
| Major bleeding | 255 | 313 |
| - Severe bleeding | 195 | 236 |
| - Major but not severe bleeding | 65 | 83 |
| participants | Clopidogrel + ASA Low Dose | Clopidogrel + ASA High Dose |
|---|---|---|
| CV death/MI/Stroke | 546 | 527 |
| - CV death | 231 | 211 |
| - MI (fatal or not) | 260 | 251 |
| - Stroke (fatal or not) | 55 | 65 |
| participants | Clopidogrel 300/75/75 mg + ASA Low Dose | Clopidogrel 300/75/75 mg + ASA High Dose | Clopidogrel 600/150/75 mg + ASA Low Dose | Clopidogrel 600/150/75 mg + ASA High Dose |
|---|---|---|---|---|
| First Occurrence of CV Death / MI / Stroke - Interaction Clopidogrel Treatment Regimen and ASA Dose Level | 267 | 290 | 282 | 240 |
| participants | Clopidogrel 300/75/75 mg + ASA | Clopidogrel 600/150/75 mg + ASA |
|---|---|---|
| CV death/MI/Stroke | 392 | 330 |
| - CV death | 132 | 130 |
| - MI (fatal or not) | 225 | 172 |
| - Stroke (fatal or not) | 35 | 28 |
| participants | Clopidogrel + ASA Low Dose | Clopidogrel + ASA High Dose |
|---|---|---|
| Major bleeding | 285 | 282 |
| - Severe bleeding | 215 | 216 |
| - Major but not severe bleeding | 74 | 73 |
This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC.
| participants | Clopidogrel 300/75/75 mg + ASA | Clopidogrel 600/150/75 mg + ASA |
|---|---|---|
| Stent trombosis | 200 | 135 |
| - Definite | 111 | 58 |
| - Probable | 89 | 77 |
Collected over 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Clopidogrel 300/75/75 mg + ASA Low Dose | — | 322/6,312 (5.1%) | 0/6,312 (0%) |
| Clopidogrel 300/75/75 mg + ASA High Dose | — | 329/6,254 (5.3%) | 0/6,254 (0%) |
| Clopidogrel 600/150/75 mg + ASA Low Dose | — | 372/6,267 (5.9%) | 0/6,267 (0%) |
| Clopidogrel 600/150/75 mg + ASA High Dose | — | 332/6,253 (5.3%) | 0/6,253 (0%) |
| Event | Clopidogrel 300/75/75 mg + ASA Low Dose | Clopidogrel 300/75/75 mg + ASA High Dose | Clopidogrel 600/150/75 mg + ASA Low Dose | Clopidogrel 600/150/75 mg + ASA High Dose |
|---|---|---|---|---|
| Operative haemorrhageInjury, poisoning and procedural complications | 39/6312 | 50/6254 | 57/6267 | 48/6253 |
| Puncture site haemorrhageGeneral disorders | 17/6312 | 21/6254 | 22/6267 | 31/6253 |
| PneumoniaInfections and infestations | 21/6312 | 11/6254 | 22/6267 | 16/6253 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 12/6312 | 16/6254 | 18/6267 | 6/6253 |
| Renal failure acuteRenal and urinary disorders | 11/6312 | 9/6254 | 18/6267 | 10/6253 |
| Pericardial haemorrhageCardiac disorders | 15/6312 | 12/6254 | 18/6267 | 11/6253 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 13/6312 | 12/6254 | 15/6267 | 15/6253 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 5/6312 | 7/6254 | 5/6267 | 10/6253 |
| Vascular pseudoaneurysmInjury, poisoning and procedural complications | 7/6312 | 8/6254 | 7/6267 | 9/6253 |
| Retroperitoneal haemorrhageGastrointestinal disorders | 2/6312 | 4/6254 | 9/6267 | 8/6253 |
| Age Continuous(years) | Clopidogrel 300/75/75 mg + ASA Low Dose | Clopidogrel 300/75/75 mg + ASA High Dose | Clopidogrel 600/150/75 mg + ASA Low Dose | Clopidogrel 600/150/75 mg + ASA High Dose | Total |
|---|---|---|---|---|---|
| Mean | 61.3 ± 11.7 | 61.5 ± 11.7 | 61.2 ± 11.8 | 61.4 ± 11.9 | 61.3 ± 11.8 |
| Age, Customized(participants) | Clopidogrel 300/75/75 mg + ASA Low Dose | Clopidogrel 300/75/75 mg + ASA High Dose | Clopidogrel 600/150/75 mg + ASA Low Dose | Clopidogrel 600/150/75 mg + ASA High Dose | Total |
|---|---|---|---|---|---|
| < 65 years | 3792 | 3740 | 3787 | 3735 | 15054 |
| 65 - 74 years | 1573 | 1576 | 1543 | 1543 | 6235 |
| ≥ 75 years | 947 | 937 | 937 | 975 | 3796 |
| Missing | 0 | 1 | 0 | 0 | 1 |
| Sex: Female, Male(Participants) | Clopidogrel 300/75/75 mg + ASA Low Dose | Clopidogrel 300/75/75 mg + ASA High Dose | Clopidogrel 600/150/75 mg + ASA Low Dose | Clopidogrel 600/150/75 mg + ASA High Dose | Total |
|---|---|---|---|---|---|
| Female | 1702 | 1756 | 1671 | 1742 | 6871 |
| Male | 4610 | 4498 | 4596 | 4511 | 18215 |
| Region of Enrollment(participants) | Clopidogrel 300/75/75 mg + ASA Low Dose | Clopidogrel 300/75/75 mg + ASA High Dose | Clopidogrel 600/150/75 mg + ASA Low Dose | Clopidogrel 600/150/75 mg + ASA High Dose | Total |
|---|---|---|---|---|---|
| Argentina | 182 | 159 | 162 | 174 | 677 |
| Australia | 97 | 100 | 96 | 95 | 388 |
| Austria | 41 | 35 | 35 | 40 | 151 |
| Belgium | 55 | 61 | 59 | 53 | 228 |
| Brazil | 292 | 275 | 270 | 288 | 1125 |
| Bulgaria | 111 | 122 | 125 | 112 | 470 |
| Canada | 349 | 379 | 373 | 347 | 1448 |
| Chile | 95 | 85 | 82 | 90 | 352 |
| China | 510 | 492 | 500 | 515 | 2017 |
| Croatia | 114 | 145 | 144 | 114 | 517 |
| Czech Republic | 257 | 275 | 277 | 258 | 1067 |
| Estonia | 1 | 0 | 0 | 1 | 2 |
| Finland | 132 | 127 | 127 | 132 | 518 |
| France | 177 | 163 | 165 | 175 | 680 |
| Germany | 471 | 450 | 453 | 470 | 1844 |
| Greece | 20 | 21 | 23 | 21 | 85 |
| India | 658 | 650 | 645 | 646 | 2599 |
| Ireland | 24 | 13 | 15 | 23 | 75 |
| Israel | 286 | 272 | 275 | 282 | 1115 |
| Italy | 232 | 260 | 258 | 231 | 981 |
| Korea, Republic of | 161 | 149 | 152 | 165 | 627 |
| Latvia | 16 | 16 | 15 | 15 | 62 |
| Lithuania | 26 | 31 | 30 | 28 | 115 |
| Malaysia | 29 | 39 | 39 | 28 | 135 |
| Mexico | 16 | 17 | 19 | 17 | 69 |
| Netherlands | 46 | 48 | 48 | 46 | 188 |
| New Zealand | 36 | 31 | 29 | 29 | 125 |
| Poland | 365 | 322 | 325 | 362 | 1374 |
| Romania | 47 | 30 | 33 | 48 | 158 |
| Russian Federation | 132 | 137 | 138 | 131 | 538 |
| Singapore | 10 | 13 | 15 | 10 | 48 |
| Slovakia | 93 | 84 | 83 | 92 | 352 |
| South Africa | 24 | 14 | 14 | 23 | 75 |
| Spain | 264 | 276 | 283 | 263 | 1086 |
| Sweden | 10 | 11 | 9 | 10 | 40 |
| Switzerland | 51 | 64 | 64 | 48 | 227 |
| Turkey | 79 | 96 | 94 | 78 | 347 |
| United Kingdom | 28 | 29 | 34 | 28 | 119 |
| United States | 775 | 763 | 759 | 765 | 3062 |
| Qualifying condition(participants) | Clopidogrel 300/75/75 mg + ASA Low Dose | Clopidogrel 300/75/75 mg + ASA High Dose | Clopidogrel 600/150/75 mg + ASA Low Dose | Clopidogrel 600/150/75 mg + ASA High Dose | Total |
|---|---|---|---|---|---|
| Suspected Unstable Angina (UA) | 1809 | 1771 | 1757 | 1877 | 7214 |
| Suspected MI without ST elevation (NSTEMI) | 2662 | 2662 | 2668 | 2539 | 10531 |
| MI with ST elevation (STEMI) | 1839 | 1817 | 1839 | 1832 | 7327 |
| Missing | 2 | 4 | 3 | 5 | 14 |
| Intended PCI performed(participants) | Clopidogrel 300/75/75 mg + ASA Low Dose | Clopidogrel 300/75/75 mg + ASA High Dose | Clopidogrel 600/150/75 mg + ASA Low Dose | Clopidogrel 600/150/75 mg + ASA High Dose | Total |
|---|---|---|---|---|---|
| Yes | 4377 | 4326 | 4262 | 4298 | 17263 |
| No | 1935 | 1928 | 2005 | 1955 | 7823 |
The record gives a start of Jun 2006, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clopidogrel